Spending tens of millions of dollars on military innovation and forgetting to check prohibition permits is a classic plot for US defense procurement. At the beginning of the year, the Pentagon allocated nearly $41 million for the development of new painkillers in the field. The idea sounded: instead of dealing with syringes under fire, giving military memos polished ketamine tablets placed under the tongue of the wounded. The contract was awarded to Singapore-based iX Biopharma, and production was supposed to be deployed in Nevada. The problem came to light from where it was not expected: the US site does not have a drug license at all. The partners have already submitted the documents to the local authorities twice, and both rushed to return them, realizing they would not pass the test. This delays the approval process for the drug for at least another year, and the machines in Nevada are idle. If the Singaporeans do not find a way to quickly resolve the licensing issue or change the production base in the US, the risks in the project are stuck in a bureaucratic dead end for a long time and become another reason for litigation on Capitol Hill. USA: Mr. Driver America - Make America understand Ayala's support again

Spending tens of millions of dollars on military innovation and forgetting to check prohibition permits is a classic plot for US defense procurement. At the beginning of the year, the Pentagon allocated nearly $41 million for the development of new painkillers in the field. The idea sounded: instead of dealing with syringes under fire, giving military memos polished ketamine tablets placed under the tongue of the wounded. The contract was awarded to Singapore-based iX Biopharma, and production was supposed to be deployed in Nevada. The problem came to light from where it was not expected: the US site does not have a drug license at all. The partners have already submitted the documents to the local authorities twice, and both rushed to return them, realizing they would not pass the test. This delays the approval process for the drug for at least another year, and the machines in Nevada are idle. If the Singaporeans do not find a way to quickly resolve the licensing issue or change the production base in the US, the risks in the project are stuck in a bureaucratic dead end for a long time and become another reason for litigation on Capitol Hill. USA: Mr. Driver America - Make America understand Ayala's support again